Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2001, Vol.84 (2), p.170-178 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 2 |
| container_start_page | 170 |
| container_title | British journal of cancer |
| container_volume | 84 |
| creator | Vasey, P A Atkinson, R Coleman, R Crawford, M Cruickshank, M Eggleton, P Fleming, D Graham, J Parkin, D Paul, J Reed, N S Kaye, S B |
| description | A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28–85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m
2
); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to toxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4%) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II–III neurotoxicity (all sensory; no motor > grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66% (49/74); CA125 response was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3–19.1). Recommended doses are carboplatin AUC 5 (via
51
Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m
2
. A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment. © 2001 Cancer Research Campaign
http://www.bjcancer.com |
| doi_str_mv | 10.1054/bjoc.2000.1572 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1008688281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-9ecfee3b5514d4953df86477b037e06976fc6e7598040ca01068c33c934a561d3</originalsourceid><addsrcrecordid>eNp1kEtv2zAQhImiQe2kvfZYCO1ZNh8iKV4KFEnzAILkkp6JFb2KaciiSspG_O9Dw0Yeh5yI4X47OxhCvjM6Y1RW82YV3IxTmqXU_BOZMil4yWquP5Np_tYlNZxOyGlKqywNrfUXMmGMKSY0n5K7i-BwhCfsSgexCUMHo-8LSEXrYxqLzvdYuCWuw7jECMOuaEMscPBZdh66ImwheugLB73D-JWctNAl_HZ8z8i_y78P59fl7f3Vzfmf29LJyoylQdciikZKVi0qI8WirVWldUOFRqqMVq1TqKWpaUUdUEZV7YRwRlQgFVuIM_L74DtsmjUuHPZjhM4O0a8h7mwAb99Per-0j2FruVBC0zob_DwaxPB_g2m0q7CJfc5sOTdGyUrIDM0OkIshpYjtywFG7b5-u6_f7uu3-_rzwo-3sV7xY98Z-HUEIDno2phb8-mFM9TUXGRqfqBSHvSPGF_DfXD4GZ0gncA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229965435</pqid></control><display><type>article</type><title>Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Vasey, P A ; Atkinson, R ; Coleman, R ; Crawford, M ; Cruickshank, M ; Eggleton, P ; Fleming, D ; Graham, J ; Parkin, D ; Paul, J ; Reed, N S ; Kaye, S B</creator><creatorcontrib>Vasey, P A ; Atkinson, R ; Coleman, R ; Crawford, M ; Cruickshank, M ; Eggleton, P ; Fleming, D ; Graham, J ; Parkin, D ; Paul, J ; Reed, N S ; Kaye, S B</creatorcontrib><description>A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28–85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m
2
); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to toxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4%) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II–III neurotoxicity (all sensory; no motor > grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66% (49/74); CA125 response was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3–19.1). Recommended doses are carboplatin AUC 5 (via
51
Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m
2
. A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment. © 2001 Cancer Research Campaign
http://www.bjcancer.com</description><identifier>ISSN: 0007-0920</identifier><identifier>ISSN: 1532-1827</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1054/bjoc.2000.1572</identifier><identifier>PMID: 11161372</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - pathology ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carboplatin - administration & dosage ; Carboplatin - adverse effects ; Chemotherapy ; Constipation - chemically induced ; Diarrhea - chemically induced ; Dose-Response Relationship, Drug ; Drug Resistance ; Epidemiology ; Fatigue - chemically induced ; Female ; Hematologic Diseases - chemically induced ; Humans ; Medical sciences ; Middle Aged ; Molecular Medicine ; Nausea - chemically induced ; Neoplasm Staging ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Paclitaxel - administration & dosage ; Paclitaxel - adverse effects ; Paclitaxel - analogs & derivatives ; Pharmacology. Drug treatments ; Prospective Studies ; Regular ; regular-article ; Survival Analysis ; Taxoids ; Treatment Outcome ; Vomiting - chemically induced</subject><ispartof>British journal of cancer, 2001, Vol.84 (2), p.170-178</ispartof><rights>The Author(s) 2001</rights><rights>2001 INIST-CNRS</rights><rights>Copyright 2001 Cancer Research Campaign.</rights><rights>Copyright Nature Publishing Group Jan 2001</rights><rights>Copyright © 2001 Cancer Research Campaign 2001 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-9ecfee3b5514d4953df86477b037e06976fc6e7598040ca01068c33c934a561d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363708/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363708/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4010,27900,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=909823$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11161372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vasey, P A</creatorcontrib><creatorcontrib>Atkinson, R</creatorcontrib><creatorcontrib>Coleman, R</creatorcontrib><creatorcontrib>Crawford, M</creatorcontrib><creatorcontrib>Cruickshank, M</creatorcontrib><creatorcontrib>Eggleton, P</creatorcontrib><creatorcontrib>Fleming, D</creatorcontrib><creatorcontrib>Graham, J</creatorcontrib><creatorcontrib>Parkin, D</creatorcontrib><creatorcontrib>Paul, J</creatorcontrib><creatorcontrib>Reed, N S</creatorcontrib><creatorcontrib>Kaye, S B</creatorcontrib><title>Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28–85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m
2
); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to toxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4%) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II–III neurotoxicity (all sensory; no motor > grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66% (49/74); CA125 response was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3–19.1). Recommended doses are carboplatin AUC 5 (via
51
Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m
2
. A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment. © 2001 Cancer Research Campaign
http://www.bjcancer.com</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carboplatin - administration & dosage</subject><subject>Carboplatin - adverse effects</subject><subject>Chemotherapy</subject><subject>Constipation - chemically induced</subject><subject>Diarrhea - chemically induced</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Fatigue - chemically induced</subject><subject>Female</subject><subject>Hematologic Diseases - chemically induced</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Nausea - chemically induced</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - adverse effects</subject><subject>Paclitaxel - analogs & derivatives</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Regular</subject><subject>regular-article</subject><subject>Survival Analysis</subject><subject>Taxoids</subject><subject>Treatment Outcome</subject><subject>Vomiting - chemically induced</subject><issn>0007-0920</issn><issn>1532-1827</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kEtv2zAQhImiQe2kvfZYCO1ZNh8iKV4KFEnzAILkkp6JFb2KaciiSspG_O9Dw0Yeh5yI4X47OxhCvjM6Y1RW82YV3IxTmqXU_BOZMil4yWquP5Np_tYlNZxOyGlKqywNrfUXMmGMKSY0n5K7i-BwhCfsSgexCUMHo-8LSEXrYxqLzvdYuCWuw7jECMOuaEMscPBZdh66ImwheugLB73D-JWctNAl_HZ8z8i_y78P59fl7f3Vzfmf29LJyoylQdciikZKVi0qI8WirVWldUOFRqqMVq1TqKWpaUUdUEZV7YRwRlQgFVuIM_L74DtsmjUuHPZjhM4O0a8h7mwAb99Per-0j2FruVBC0zob_DwaxPB_g2m0q7CJfc5sOTdGyUrIDM0OkIshpYjtywFG7b5-u6_f7uu3-_rzwo-3sV7xY98Z-HUEIDno2phb8-mFM9TUXGRqfqBSHvSPGF_DfXD4GZ0gncA</recordid><startdate>2001</startdate><enddate>2001</enddate><creator>Vasey, P A</creator><creator>Atkinson, R</creator><creator>Coleman, R</creator><creator>Crawford, M</creator><creator>Cruickshank, M</creator><creator>Eggleton, P</creator><creator>Fleming, D</creator><creator>Graham, J</creator><creator>Parkin, D</creator><creator>Paul, J</creator><creator>Reed, N S</creator><creator>Kaye, S B</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>2001</creationdate><title>Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer</title><author>Vasey, P A ; Atkinson, R ; Coleman, R ; Crawford, M ; Cruickshank, M ; Eggleton, P ; Fleming, D ; Graham, J ; Parkin, D ; Paul, J ; Reed, N S ; Kaye, S B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-9ecfee3b5514d4953df86477b037e06976fc6e7598040ca01068c33c934a561d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carboplatin - administration & dosage</topic><topic>Carboplatin - adverse effects</topic><topic>Chemotherapy</topic><topic>Constipation - chemically induced</topic><topic>Diarrhea - chemically induced</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Fatigue - chemically induced</topic><topic>Female</topic><topic>Hematologic Diseases - chemically induced</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Nausea - chemically induced</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - adverse effects</topic><topic>Paclitaxel - analogs & derivatives</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Regular</topic><topic>regular-article</topic><topic>Survival Analysis</topic><topic>Taxoids</topic><topic>Treatment Outcome</topic><topic>Vomiting - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vasey, P A</creatorcontrib><creatorcontrib>Atkinson, R</creatorcontrib><creatorcontrib>Coleman, R</creatorcontrib><creatorcontrib>Crawford, M</creatorcontrib><creatorcontrib>Cruickshank, M</creatorcontrib><creatorcontrib>Eggleton, P</creatorcontrib><creatorcontrib>Fleming, D</creatorcontrib><creatorcontrib>Graham, J</creatorcontrib><creatorcontrib>Parkin, D</creatorcontrib><creatorcontrib>Paul, J</creatorcontrib><creatorcontrib>Reed, N S</creatorcontrib><creatorcontrib>Kaye, S B</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vasey, P A</au><au>Atkinson, R</au><au>Coleman, R</au><au>Crawford, M</au><au>Cruickshank, M</au><au>Eggleton, P</au><au>Fleming, D</au><au>Graham, J</au><au>Parkin, D</au><au>Paul, J</au><au>Reed, N S</au><au>Kaye, S B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2001</date><risdate>2001</risdate><volume>84</volume><issue>2</issue><spage>170</spage><epage>178</epage><pages>170-178</pages><issn>0007-0920</issn><issn>1532-1827</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28–85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m
2
); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to toxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4%) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II–III neurotoxicity (all sensory; no motor > grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66% (49/74); CA125 response was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3–19.1). Recommended doses are carboplatin AUC 5 (via
51
Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m
2
. A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment. © 2001 Cancer Research Campaign
http://www.bjcancer.com</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>11161372</pmid><doi>10.1054/bjoc.2000.1572</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2001, Vol.84 (2), p.170-178 |
| issn | 0007-0920 1532-1827 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363708 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carboplatin - administration & dosage Carboplatin - adverse effects Chemotherapy Constipation - chemically induced Diarrhea - chemically induced Dose-Response Relationship, Drug Drug Resistance Epidemiology Fatigue - chemically induced Female Hematologic Diseases - chemically induced Humans Medical sciences Middle Aged Molecular Medicine Nausea - chemically induced Neoplasm Staging Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Paclitaxel - administration & dosage Paclitaxel - adverse effects Paclitaxel - analogs & derivatives Pharmacology. Drug treatments Prospective Studies Regular regular-article Survival Analysis Taxoids Treatment Outcome Vomiting - chemically induced |
| title | Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T16%3A30%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Docetaxel-carboplatin%20as%20first%20line%20chemotherapy%20for%20epithelial%20ovarian%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Vasey,%20P%20A&rft.date=2001&rft.volume=84&rft.issue=2&rft.spage=170&rft.epage=178&rft.pages=170-178&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1054/bjoc.2000.1572&rft_dat=%3Cproquest_pubme%3E1008688281%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229965435&rft_id=info:pmid/11161372&rfr_iscdi=true |